University of Colorado Denver, Medical Director of the Rocky Mountain Multiple Sclerosis Center Professor of Neurology and Co-Director of the RMMSC at Anschutz Dr. Timothy Vollmer said, "Previous Phase III studies in more than 2,400 people with RRMS suggest a unique profile of Laquinimod, directly affecting the neurodegenerative processes that lead to disability progression, the main concern in the treatment of RRMS. We are currently enrolling patients in this third pivotal study to further examine the clinical benefits of Laquinimod on disability progression, the primary endpoint of the CONCERTO trial, and brain atrophy, at both the previously studied 0.6 mg dose, and now a higher 1.2 mg dose."
The multinational, randomized, double blind placebo-controlled study will aim to enroll 1,800 patients at more than 300 sites globally. Along with the primary endpoint of time to confirmed disability progression, the study will also examine the impact of Laquinimod on endpoints such as percent change in brain volume and other clinical and MRI markers of disease activity.
Teva president of global R&D and chief scientific officer Dr. Michael Hayden said, "For nearly 30 years, Teva has been focused on improving the lives of people with multiple sclerosis by delivering innovative treatment options that address this complex disease. The CONCERTO study demonstrates our commitment to collaborating with MS communities worldwide to further develop Laquinimod and address unmet patient needs."
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments